Abstract:
Title compd.(I; X1,Y1 = O, H, OH; R2 = C3-7 alkyl), were prepd. by hydrolysis of Ib obtained from Ia (R3 = protecting group). Compd. Ia was obtained by reaction of XVII and (R4)3P=CH-COOCh3 (R4=C1-4 alkyl, Ph). Thus, 190mg 1-[4-(1-formyl-3-hydroxy)-butyl-2-(3-hydroxy-1-octenyl-3, 5-dihydroxy-cyclopentane and 20mg carbomethoxymethylene-triphenylphosphorane were stirred at room temp for 16hr in 10ml anhyd. benzene to give 6,9,11,15-tetrahydroxy-(E)-2, (E)-13-prostadienic methyl ester.
Abstract:
Title compds. (I; R1,R2 = O; R3,R4 = C1-5 alkyl ; R5 = tetrahydropyranyl, H ; U = (CH2)0-5, cis- or trans-alkyl = c-alkyl; V = simple bond, O, furan, benzyl ; W = alkyl-C-alkyl; X = (CH2)0-4), similar in structure to natural prostaglandine, having strong antiprostaglandine activity were prepd. by reaction of II and in aprotic solvent. Thus, 3.66g (5RS,3'RS)-2-oxo-5 3'-(2"-tetrahydropyranyloxy) -trans-1'-octenyl -cyclopentane-carboxylic ester in C6H5CH3 were stirred with 1.35g potassium-t-butylate followed by reaction with 4g 7-iodo-heptanophosphoric ethyl ester to give I.
Abstract:
Title compds. (I; R1 = H, C1-8 alkyl radical, C1-6 unsaturated aliphatic radical, C3-7 ring aliphatic radical, metal ion, NH4+ ion, ammonium ion, tetraalkylammonium ion; R2 = C3-7 cycloalkyl radical, C1-8 alkyl radical) sere prepd. by elimination of R3 from V(R3 = protecting group) obtained from IV. Compd. IV was prepd. by the acid hydrolysis of III obtained from II(X = halogen).
Abstract:
1-(1-Imidazolyl)-isoquinolines of the general formula I and their physiologically tolerated salts,
IN WHICH R1, R2 and R3 represent hydrogen, alkyl of 1 to 4 carbon atoms or phenyl, R1, R2 and R3 may be identical or different, R4 represents hydrogen, alkyl of 1 to 4 carbon atoms, phenyl or chlorine, and R5 represents hydrogen, alkyl of 1 to 6 carbon atoms, cycloalkyl of 5 to 8 carbon atoms, phenyl or chlorine, a process for preparing them and pharmaceutical preparations containing them as active ingredient.
Abstract:
Compounds having a coginition adjuvant action, agents containing them and the use thereof in the treatment and prophylaxis of cognitive dysfunctions The invention relates to new compounds having a cognition adjuvant action, to the use of ACE inhibitors as medicaments having a cognition adjuvant action, to agents containing them, and to the use thereof for the treatment and prophylaxis of cognitive dysfunctions.
Abstract:
A process for the preparation of racemic and optically active 1,2.3,4-tetrahydroisoquinoline-3-carboxylic acid is described, in which dihalo-o-xylylenes are cyclized to dicarboxylic acid esters in basic medium using dialkyl N-acylamidomalonates of the formula (CO2R1)2CHNHCOR2, in which R1 is (C1-C4)-alkyl and R2 is H, (C1-C4)-alkyl or (C6-C12)-aryl, decarboxylated by basic hydrolysis and subsequent acid work-up and then reacted in acid medium to give (D,L)-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid, or dihalo-o-xylylenes are cyclized in basic medium to give the dicarboxylic acid esters and these are reacted directly without isolation in a one-pot process to give (D,L)-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid, if desired the racemic 1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid is reacted with (-)menthol and p-toluenesulfonic acid to give (-)menthyl (D)- or (L)-1,2,3,4-tetrahydroisoquinoline-3-carboxylate, then the diastereomers are separated by column chromatography and subjected to basic hydrolysis to give (D)-or (L)-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid, or (D,L)-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid is esterified by means of benzyl alcohol and p-toluenesulfonic acid, reacted with D(-)mandelic acid to give benzyl (D)-1,2,3,4-tetrahydroisoquinoline-3-carboxylate (D)-mandelate and benzyl (L)-1,2,3,4-tetrahydroisoquinoline-3-carboxylate (D)-mandelate or with L(+)mandelic acid to give benzyl (D)-1,2,3,4-tetrahydroisoquinoline-3-carboxylate (L)-mandelate and benzyl (L)-1,2,3,4-tetrahydroisoquinoline-3-carboxylate (L)-mandelate and then the compounds obtained are separated into the optical antipodes by fractional crystallization in an inert solvent and the enantiomers (D)- or (L)-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid are liberated by basic hydrolysis, the chiral auxiliary reagent being recovered.
Abstract:
The invention relates to novel compounds having a nootropic activity, the use of ACE inhibitors as medicaments having nootropic activity, agents containing them, and their use in the treatment and prophylaxis of cognitive malfunctions.
Abstract:
The invention relates to novel compounds having a nootropic activity, the use of ACE inhibitors as medicaments having nootropic activity, agents containing them, and their use in the treatment and prophylaxis of cognitive malfunctions.
Abstract:
Compounds of the formula I (I) where R(1), R(2), R(3), R(4) and R(5) are, inter alia, hydrogen and alkyl, m is 1-4, n is 0 or 1, p is 0-4 and R(6) is identical or different dialkylamine derivatives, and salts thereof, have a calcium-antagonistic action. They are obtained by reacting corresponding amines with a compound II which carries, on the side chain, a leaving group which can be displaced nucleophilically, or from a hydroxyphenyl-dihydroquinolin-2-one compound by reaction with a corresponding side chain compound which has a leaving group which can be displaced nucleophilically.